Biotest Wins German Approval for Prufibry Human Fibrinogen Therapy
I'm PortAI, I can summarize articles.
Biotest AG has received approval from the Paul-Ehrlich-Institut in Germany for its human fibrinogen therapy, Prufibry® (BT524). This therapy is aimed at patients with fibrinogen deficiency, providing a reliable solution for preventing and controlling severe bleeding, especially during surgeries and trauma. The product's approval is supported by clinical studies confirming its efficacy and safety. The market launch in Germany is anticipated by the end of 2025, with plans for further approvals in other European and international markets.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments